Literature DB >> 19880879

ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1.

Sang-Wang Lee1, Yang-Sook Cho, Jung-Min Na, Ui-Hyun Park, Myengmo Kang, Eun-Joo Kim, Soo-Jong Um.   

Abstract

We previously suggested that ASXL1 (additional sex comb-like 1) functions as either a coactivator or corepressor for the retinoid receptors retinoic acid receptor (RAR) and retinoid X receptor in a cell type-specific manner. Here, we provide clues toward the mechanism underlying ASXL1-mediated repression. Transfection assays in HEK293 or H1299 cells indicated that ASXL1 alone possessing autonomous transcriptional repression activity significantly represses RAR- or retinoid X receptor-dependent transcriptional activation, and the N-terminal portion of ASXL1 is responsible for the repression. Amino acid sequence analysis identified a consensus HP1 (heterochromatin protein 1)-binding site (HP1 box, PXVXL) in that region. Systematic in vitro and in vivo assays revealed that the HP1 box in ASXL1 is critical for the interaction with the chromoshadow domain of HP1. Transcription assays with HP1 box deletion or HP1alpha knockdown indicated that HP1alpha is required for ASXL1-mediated repression. Furthermore, we found a direct interaction of ASXL1 with histone H3 demethylase LSD1 through the N-terminal region nearby the HP1-binding site. ASXL1 binding to LSD1 was greatly increased by HP1alpha, resulting in the formation of a ternary complex. LSD1 cooperates with ASXL1 in transcriptional repression, presumably by removing H3K4 methylation, an active histone mark, but not H3K9 methylation, a repressive histone mark recognized by HP1. This possibility was supported by chromatin immunoprecipitation assays followed by ASXL1 overexpression or knockdown. Overall, this study provides the first evidence that ASXL1 cooperates with HP1 to modulate LSD1 activity, leading to a change in histone H3 methylation and thereby RAR repression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19880879      PMCID: PMC2804164          DOI: 10.1074/jbc.M109.065862

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  56 in total

Review 1.  The Polycomb group--no longer an exclusive club?

Authors:  H W Brock; M van Lohuizen
Journal:  Curr Opin Genet Dev       Date:  2001-04       Impact factor: 5.578

Review 2.  Role of protein methylation in chromatin remodeling and transcriptional regulation.

Authors:  M R Stallcup
Journal:  Oncogene       Date:  2001-05-28       Impact factor: 9.867

3.  Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain.

Authors:  A J Bannister; P Zegerman; J F Partridge; E A Miska; J O Thomas; R C Allshire; T Kouzarides
Journal:  Nature       Date:  2001-03-01       Impact factor: 49.962

4.  Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins.

Authors:  M Lachner; D O'Carroll; S Rea; K Mechtler; T Jenuwein
Journal:  Nature       Date:  2001-03-01       Impact factor: 49.962

5.  Heterochromatin dynamics in mouse cells: interaction between chromatin assembly factor 1 and HP1 proteins.

Authors:  N Murzina; A Verreault; E Laue; B Stillman
Journal:  Mol Cell       Date:  1999-10       Impact factor: 17.970

6.  Characterization of receptor-interacting protein 140 in retinoid receptor activities.

Authors:  C H Lee; L N Wei
Journal:  J Biol Chem       Date:  1999-10-29       Impact factor: 5.157

Review 7.  Retinoids in embryonal development.

Authors:  S A Ross; P J McCaffery; U C Drager; L M De Luca
Journal:  Physiol Rev       Date:  2000-07       Impact factor: 37.312

8.  Altered retinoic acid sensitivity and temporal expression of Hox genes in polycomb-M33-deficient mice.

Authors:  S Bel-Vialar; N Coré; R Terranova; V Goudot; A Boned; M Djabali
Journal:  Dev Biol       Date:  2000-08-15       Impact factor: 3.582

9.  Receptor-interacting protein 140 directly recruits histone deacetylases for gene silencing.

Authors:  L N Wei; X Hu; D Chandra; E Seto; M Farooqui
Journal:  J Biol Chem       Date:  2000-12-29       Impact factor: 5.157

10.  The histone deacetylase-3 complex contains nuclear receptor corepressors.

Authors:  Y D Wen; V Perissi; L M Staszewski; W M Yang; A Krones; C K Glass; M G Rosenfeld; E Seto
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

View more
  37 in total

Review 1.  Histone methylation in myelodysplastic syndromes.

Authors:  Yue Wei; Irene Gañán-Gómez; Sophie Salazar-Dimicoli; Sara L McCay; Guillermo Garcia-Manero
Journal:  Epigenomics       Date:  2011-04       Impact factor: 4.778

Review 2.  Molecular biology of myelodysplastic syndromes.

Authors:  Alan H Shih; Ross L Levine
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

Review 3.  Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions.

Authors:  Hideki Muramatsu; Hideki Makishima; Jaroslaw P Maciejewski
Journal:  Semin Oncol       Date:  2012-02       Impact factor: 4.929

4.  Additional sex comb-like (ASXL) proteins 1 and 2 play opposite roles in adipogenesis via reciprocal regulation of peroxisome proliferator-activated receptor {gamma}.

Authors:  Ui-Hyun Park; Seung Kew Yoon; Taesun Park; Eun-Joo Kim; Soo-Jong Um
Journal:  J Biol Chem       Date:  2010-11-03       Impact factor: 5.157

Review 5.  Molecular aspects of myeloproliferative neoplasms.

Authors:  François Delhommeau; Dorota Jeziorowska; Christophe Marzac; Nicole Casadevall
Journal:  Int J Hematol       Date:  2010-02-27       Impact factor: 2.490

6.  Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology.

Authors:  Ayalew Tefferi; Pierre Noel; Curtis A Hanson
Journal:  J Mol Diagn       Date:  2011-06-30       Impact factor: 5.568

Review 7.  Epigenetic regulators and their impact on therapy in acute myeloid leukemia.

Authors:  Friederike Pastore; Ross L Levine
Journal:  Haematologica       Date:  2016-03       Impact factor: 9.941

8.  Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.

Authors:  Anna M Jankowska; Hideki Makishima; Ramon V Tiu; Hadrian Szpurka; Yun Huang; Fabiola Traina; Valeria Visconte; Yuka Sugimoto; Courtney Prince; Christine O'Keefe; Eric D Hsi; Alan List; Mikkael A Sekeres; Anjana Rao; Michael A McDevitt; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

9.  Familial hematological malignancies: ASXL1 gene investigation.

Authors:  W S Hamadou; R E Abed; S Besbes; V Bourdon; A Fabre; Y B Youssef; M A Laatiri; F Eisinger; V Mari; P Gesta; H Dreyfus; V Bonadona; C Dugast; H Zattara; L Faivre; S Y Jemni; T Noguchi; A Khélif; H Sobol; Z Soua
Journal:  Clin Transl Oncol       Date:  2015-08-19       Impact factor: 3.405

Review 10.  Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms.

Authors:  Omar Abdel-Wahab; Ayalew Tefferi; Ross L Levine
Journal:  Hematol Oncol Clin North Am       Date:  2012-08-21       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.